Table I.
Associations between RASEF mRNA expression and clinicopathological characteristics of 167 patients with BC.
| Clinicopathological parameters | Low RASEF group (n=41) | Others (n=126) | P-value |
|---|---|---|---|
| Age (years) | 0.847 | ||
| ≤60 | 26 | 82 | |
| >60 | 15 | 44 | |
| Histology | 0.231 | ||
| DCIS | 1 | 6 | |
| IDC | 39 | 109 | |
| ILC | 0 | 6 | |
| Others | 1 | 5 | |
| UICC T factor | 0.031a | ||
| Tis/T1 | 13 | 64 | |
| T2/T3/T4 | 28 | 62 | |
| Node status | 0.164 | ||
| Negative | 17 | 68 | |
| Positive | 24 | 58 | |
| UICC pathological stage | 0.413 | ||
| 0/I/II | 34 | 97 | |
| III/IV | 7 | 29 | |
| ER status | <0.001a | ||
| Positive | 21 | 106 | |
| Negative | 20 | 20 | |
| PgR status | <0.001a | ||
| Positive | 17 | 98 | |
| Negative | 24 | 28 | |
| HER2 status | 0.873 | ||
| Positive | 10 | 29 | |
| Negative | 29 | 90 | |
| Unknown | 2 | 7 | |
| Triple-negative | <0.001a | ||
| Yes | 13 | 5 | |
| No | 27 | 121 | |
| Unknown | 1 | 0 | |
| Adjuvant therapy | 0.005a | ||
| Endocrine therapy alone | 7 | 50 | |
| Chemotherapy alone | 14 | 16 | |
| Endocrine and chemotherapy | 15 | 49 | |
| None | 5 | 11 |
a
χ2 test. RASEF, RAS and EF-hand domain-containingp; BC, breast cancer; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; UICC, Union for International Cancer Control; Tis, carcinoma in situ; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor 2.